Conference Coverage

Tenecteplase noninferior to alteplase for ischemic stroke: TRACE-2


 

FROM ISC 2023

Strong evidence

Commenting on the study findings, Larry B. Goldstein, MD, professor and chair of neurology, University of Kentucky, Lexington, said it is important to determine the efficacy of tenecteplase among Asians, as they represent “an entirely different population” with unique concerns, such as bleeding complications from anticoagulants.

He noted an advantage of tenecteplase is ease of administration. “You don’t have to go through the loading dose and then the 1-hour infusion,” which poses an “additional hassle” when transferring patients between institutions, he said.

However, he noted that a possible “downside” to having both drugs available in the emergency department is “using the wrong drug at the wrong dose” because of their similar sounding names.

Also commenting on the study, Tudor G. Jovin, MD, professor and chair, department of neurology, Rowan University, Camden, N.J., said he welcomes another trial that confirms that these two drugs are biologically similar.

“I’m very glad this trial was done because it adds another very strong piece of evidence of equivalency.”

But the two drugs are not the same in some important respects, said Dr. Jovin, whose center switched to using tenecteplase almost 3 years ago. That switch has resulted in cutting 17 minutes from the door-to-needle time “which is quite significant,” he said.

“There’s no question that once we used tenecteplase in lieu of tPA, it’s been just so much easier to administer and affects the interhospital transfer protocols, because you’re not transferring the patient with a critical care IV. It’s a win-win situation for everyone.”

The study received funding from the National Science and Technology Major Project, the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences, the National Natural Science Foundation of China, and the China Shijiazhuang Pharmaceutical Company Recomgen Pharmaceutical (Guangzhou). Dr. Li, Dr. Goldstein, and Dr. Jovin report no relevant financial relationships.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Warfarin best for thrombotic antiphospholipid syndrome?
MDedge Cardiology
After PCI, 1-month beats 12-month DAPT in high-risk patients
MDedge Cardiology
Possible bivalent vaccine link to strokes in people over 65
MDedge Cardiology
Renowned stroke expert Ralph L. Sacco, MD, dies
MDedge Cardiology
AHA scientific statement on rapid evaluation for suspected TIA
MDedge Cardiology
Canadian guidance recommends reducing alcohol consumption
MDedge Cardiology
Novel neuroprotective agent promising in stroke
MDedge Cardiology
STROKE AF at 3 years: High AFib rate after atherosclerotic stroke
MDedge Cardiology
Blood pressure lowering after thrombectomy may be harmful
MDedge Cardiology
Thrombectomy benefits stroke with large core volumes: SELECT2 trial results
MDedge Cardiology